Results 11 to 20 of about 90,593 (299)

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.

New England Journal of Medicine, 2021
BACKGROUND Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Yongjun Wang, Xia Meng, Anxin Wang, Xuewei Xie, Yuesong Pan, S. Johnston, Hao Li, P. Bath, Q. Dong, Anding Xu, J. Jing, Jinxi Lin, Siying Niu, Yilong Wang, Xingquan Zhao, Zixiao Li, Yong Jiang, Wei Li, Liping Liu, Jie Xu, L. Chang, Lihua Wang, Xianbo Zhuang, Jinguo Zhao, Yefang Feng, Honghao Man, Guozhong Li, Baojun Wang   +27 more
semanticscholar   +1 more source

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

Frontiers in Cardiovascular Medicine, 2023
BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo, Yao Lu, Fei Guo, Aihua Wu, Yuesong Weng   +4 more
doaj   +1 more source

Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study

Circulation, 2022
Background: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Extended Antiplatelet Monotherapy ...
Jeehoon Kang, Kyung-Woo Park, H. Lee, D. Hwang, Han-Mo Yang, S. Rha, J. Bae, N. Lee, S. Hur, J. Han, E. Shin, B. Koo, Hyo‐Soo Kim   +12 more
semanticscholar   +1 more source

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction

Frontiers in Pharmacology, 2021
Objective: To explore the treatment effect of statins used together with clopidogrel on cerebral infarction (CI).Methods: One hundred and thirty non-clopidogrel resistant patients were divided into a dynamic clopidogrel resistant (DCR) group and a ...
Hong Ting Shi, Yong Yuan Chen, Xiao Ying Li, Jian Hua Luo, Guang Hong Zhong, Jia Jia Hu, Min Zhang, Bo Rong Zhou   +7 more
doaj   +1 more source

Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease

Platelets, 2023
Clopidogrel combined with aspirin is widely used in coronary artery disease (CAD) patients, while some patients exhibit high platelet activity when receiving the combined treatment. Current environmental and genetic factors could only explain part of the
Xiaolei Hu, Mupeng Li, He Li, Peiyuan Song, Yanjiao Zhang, Gan Zhou, Jie Tang, Liming Peng, Qilin Ma, Xiaoping Chen   +9 more
doaj   +1 more source

Clopidogrel (Plavix) [PDF]

American Journal of Neuroradiology, 2011
Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with ...
J, Comin, D, Kallmes
openaire   +2 more sources

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2020
Importance After percutaneous coronary intervention (PCI), patients with CYP2C19*2 or *3 loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic events.
N. Pereira, M. Farkouh, D. So, R. Lennon, N. Geller, V. Mathew, M. Bell, J. Bae, M. Jeong, Ivan J. Chavez, Paul Gordon, J. Abbott, C. Cagin, L. Baudhuin, Yi-Ping Fu, S. Goodman, S. Goodman, Ahmed A Hasan, E. Iturriaga, A. Lerman, M. Sidhu, J. Tanguay, Liewei Wang, R. Weinshilboum, R. Welsh, Y. Rosenberg, K. Bailey, C. Rihal   +27 more
semanticscholar   +1 more source

Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

Journal of Pharmaceutical Health Care and Sciences, 2020
Background Repaglinide is widely prescribed to reduce postprandial hyperglycemia and elevated glycated hemoglobin (HbA1c) levels associated with type 2 diabetes, and clopidogrel is a thienopyridine antiplatelet agent and widely used in cardiovascular and
Yuuki Akagi, Akiko Iketaki, Haruna Kimura, Yuki Matsudaira, Takami Yoshida, Takahiro Nishimura, Yohei Kawano, Yasunari Mano, Erina Shigematsu, Makoto Ujihara   +9 more
doaj   +1 more source

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

New England Journal of Medicine, 2009
BACKGROUND Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén   +17 more
semanticscholar   +1 more source

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

New England Journal of Medicine, 2007
BACKGROUND Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano de Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman   +13 more
semanticscholar   +1 more source